Unicycive Therapeutics (NASDAQ:UNCY) Raised to “Hold” at Wall Street Zen

Unicycive Therapeutics (NASDAQ:UNCY) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

UNCY has been the topic of several other reports. Zacks Research lowered shares of Unicycive Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 21st. B. Riley Financial reiterated a “buy” rating and set a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday. Guggenheim reissued a “buy” rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday. Benchmark lowered their price objective on shares of Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a research report on Wednesday, July 1st. Finally, Weiss Ratings upgraded Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 9th. Five research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $18.25.

Unicycive Therapeutics Stock Performance

UNCY opened at $5.51 on Friday. Unicycive Therapeutics has a 52-week low of $3.71 and a 52-week high of $8.74. The firm has a market cap of $153.45 million, a P/E ratio of -3.15 and a beta of 1.79. The business’s fifty day moving average is $5.94 and its 200-day moving average is $6.64.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.41. On average, research analysts predict that Unicycive Therapeutics will post -1.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its holdings in Unicycive Therapeutics by 11,698.4% in the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after purchasing an additional 21,525 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Unicycive Therapeutics in the 2nd quarter valued at $55,000. Vanguard Group Inc. lifted its position in shares of Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after acquiring an additional 52,925 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Unicycive Therapeutics during the 3rd quarter valued at $512,000. Finally, Citadel Advisors LLC bought a new stake in Unicycive Therapeutics in the third quarter valued at $182,000. 40.42% of the stock is owned by institutional investors and hedge funds.

Key Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $15 price target, substantially above the stock’s recent trading level. The firm slightly improved its FY2026 EPS forecast to a $1.43 loss from a $1.45 loss, signaling a marginally better near-term outlook.
• Positive Sentiment: Noble Financial made several favorable near-term revisions, raising its Q3 2026 forecast to a $0.23 loss from a $0.35 loss and its Q4 2026 forecast to a $0.25 loss from a $0.38 loss. Noble also improved its FY2026 forecast to a $0.62 loss from a $1.62 loss. Noble Financial Analysts Lower Earnings Estimates for UNCY
• Neutral Sentiment: Noble Financial lowered its Q1 2027 EPS estimate to $0.64 from $0.85 and its FY2027 estimate to $3.70 from $4.33, although it still projects a transition to profitability in 2027.
• Neutral Sentiment: Wall Street Zen raised Unicycive to a Hold rating, suggesting a more balanced stance on the shares. Unicycive Therapeutics Raised to Hold at Wall Street Zen
• Negative Sentiment: HC Wainwright reduced multiple forecasts, including Q3 and Q4 2026 EPS to losses of $0.40 and $0.42, respectively, and FY2027 EPS to a $1.05 loss from a $0.37 loss.
• Negative Sentiment: HC Wainwright also cut its projected long-term profitability: FY2028 EPS fell to $1.98 from $3.04, FY2029 to $3.08 from $4.57, and FY2030 to $3.11 from $5.42. These revisions imply slower earnings growth, despite the unchanged Buy rating and $15 target.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.